Likmez (Metronidazole) Patent Expiration, LOE Window & CMS Spending
Likmez (Metronidazole) by Saptalis: FDA Orange Book LOE 2039-10-04, 35 AB generics, $1.1M 2024 CMS Part D & Medicaid spend.
| Regulatory & Reimbursement Dimension | Verified Value |
|---|---|
| Consolidated Sponsor | Saptalis |
| FDA Application & Pathway | N216755 (NDA) |
| Exclusivity / Cliff Horizon | Long-Dated Protection (2036+) |
| Core Active-Ingredient LOE Date | Not listed / N/A |
| Last Listed Patent or Exclusivity Date | 2039-10-04 |
| Orange Book Patents (*PED Extensions) | 2 patents (0 *PED) |
| Active AB-Rated Generic Competitors | 35 |
| 2024 CMS Total Public Spend | $1.1M |
| 2024 Medicare Part D Spend | $0 |
| 2024 Medicaid Spend | $1.1M |
| Reported Wholesale Price Change (CA SB 17) | 0 statutory filings in 2023 to 2026 panel |